NCT06379139

Brief Summary

Biofilm is a microstructure organised into aggregates of microbiological species within a polymeric matrix. As early as the 2000s, the Centers for Disease Control and Prevention (CDC) recognised the possible role of the biofilm lining endotracheal endotracheal tubes in the development of ventilator-associated pneumonia (VAP) , the most common infection in intensive care, with a high morbidity and mortality rate and a significant increase in hospital costs. Targeting biofilm therefore now appears to be a new area of interest for limiting the risk of VAP, and this rationale has led to the development of an intraluminal for abrading biofilm deposited on the inside of the intubation probe . Evaluation of this type of strategy nevertheless justifies the introduction of more precise methods for characterisation of the biofilm. To this end, the investigator carried out an initial clinical study describing the biofilm on intubation probes, BIOPAVIR 1, showing the existence of several biofilm structures, each associated with a specific microbiological signature. Several limitations including a lack of power due to an insufficient number of patients and the use of number of patients, and the use of a confocal microscopy technique with poor axial without the possibility of acquiring metabolic images of the biofilm. Based on the previous description of biofilm by optical coherence tomography (OCT), and a recent experience with an optimised form of high-resolution OCT, called full-field OCT, the investigator hypothesise that full-field OCT will allow more accurate characterisation of biofilm, due to its high spatial resolution and its potential ability to capture metabolic activity in the biofilm BIOPAVIR 2 proposes to use the performance of full-field OCT to better characterise the biofilm lining endotracheal tubes in patients undergoing mechanical ventilation in intensive care units. This project represents a first step towards understanding the link between the development of biofilm on intubation and the occurrence of VAP

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2024

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 4, 2024

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 23, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2025

Completed
Last Updated

April 23, 2024

Status Verified

April 1, 2024

Enrollment Period

1 year

First QC Date

April 4, 2024

Last Update Submit

April 22, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Dynamic Full-Field Optical Coherence Tomography-based biofilm structure type

    shape data

    At Day 0, within 72hours following endothracheal tube removal

  • type of microbiological associated with each shape

    At Day 0, within 72hours following endothracheal tube removal

Study Arms (1)

BIOPAVIR 2 cohort

Adult critically ill patients (\> 18 years of age) exposed to endotracheal tube for at least two calendar days

Other: •Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube

Interventions

Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm

BIOPAVIR 2 cohort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient over 18 years of age having declared their nonobjection and exposed to mechanical ventilation for at least two calendar days

You may qualify if:

  • Patient or relative informed of the study and having declared their nonobjection
  • Patient over 18 years of age
  • Patient exposed to mechanical ventilation for at least two calendar days

You may not qualify if:

  • Patient unable to declare their nonobjection
  • Patient whose endotracheal tube collection is impossible
  • Patient whose endotracheal tube is collected following self-extubation (sample contamination)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CH William Morey

Chalon-sur-Saône, France

RECRUITING

CHU Dijon Bourgogne

Dijon, France

RECRUITING

MeSH Terms

Conditions

Cross InfectionCritical Illness

Condition Hierarchy (Ancestors)

InfectionsIatrogenic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Thomas MALDINEY

    CH William Morey

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2024

First Posted

April 23, 2024

Study Start

March 1, 2024

Primary Completion

March 1, 2025

Study Completion

March 1, 2025

Last Updated

April 23, 2024

Record last verified: 2024-04

Locations